The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 15.9% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 57% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 46%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (1 analysts) rates it none, with a mean price target of $70. Insiders have been net sellers over the past quarter. Since the last review it its composite score rose.
Pro-Dex Inc
PDEX · NASDAQ · USD · Market cap $232M · 179 employees
Pro-Dex, Inc.
PASS · Titan Ethical · score 70.0Screen close, 2026-09-21 · not a live quote
Last reviewed 15 days ago
Screened 2026-09-21 · the tape above runs as of 13:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
What this means: price 72.52 against the desk's fair-value range, base estimate 69.96, over the last year.
- Trend Markup
- Insiders insiders sold, $45,412, latest filing 2026-09-11
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical passes the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
Pro-Dex Inc holds its Markup at $72.52. The statistical read favours the buyers, held for 127 days.
| Phase | Markup |
| Quantitative state | The statistical read favours the buyers, held for 127 days |
| Price at the screen | $72.52 |
| Valuation | 17.60 trailing · 21.58 forward price to earnings |
| Values screen | PASS · score 70.0 |
| Beta | 0.06 |
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 27.09% | Below 33% | Interest-bearing debt is just 27.1% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 11.01% | Below 33% | Cash held in interest-bearing accounts and securities is 11.0% of assets, under the one-third limit. | Pass |
| Receivables | 27.54% | Below 49% | Money owed to the company is 27.5% of assets, under the 49% limit. | Pass |
| Revenue purity | 0.12% | Below 5% | Only 0.1% of revenue comes from non-compliant sources, under the 5% line. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Clears, in Plain English
Pro-Dex clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 27%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-10-04. It updates when the underlying figures move, and past reads are kept below.
What the Numbers Say It Is WorthThe Fair Value Range
Fair value range in USD, drawn from the 2026-09-21 screen. The gold marker is the market price at the same screen. The price runs 3.5% above the base estimate.
Reading the gap · Both our model and the Street see limited upside at this price.
Price History & ProjectionsWhere it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-21 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words| Forward P/E | 21.6xpriced for continued growth |
| Trailing P/E | 17.6xreasonably valued |
| EPS, trailing | 4.12 |
| EPS, forward | 3.36 |
| Revenue growth | +16.6%steady growth |
| Profit margin | 17.6%healthy profit margins |
| Return on equity | 32.4%an exceptional return on shareholder capital |
| FCF yield | 2.33% |
| Debt to equity | 0.40minimal debt: a conservative balance sheet |
| Current ratio | 4.10comfortably covers its short-term bills |
| Beta | 0.06barely tracks the market's swings |
| Short interest, float | 0.25% |
| 52-week range | 23.47 - 77.00 |
| Moat | NONE |
| Market cap | $232M |
| Employees | 179 |
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradePDEX trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 9.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 57% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 46%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (1 analysts) rates it none, with a mean price target of $70.
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 7.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 57% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 46%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (1 analysts) rates it none, with a mean price target of $70.
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 57% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 46%. Our forward projection puts the odds of a 10% gain over the next month near 42%. The street (1 analysts) rates it none, with a mean price target of $70.
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Best Momentum Stocks to Buy for September 18th Zacks · 18d ago
- New Strong Buy Stocks for September 18th Zacks · 18d ago
- Dell Afterglow Continues. These Other Stocks Top Buy Points. Investor's Business Daily · 4 Sep 2026
- Vivos Therapeutics, Inc. (VVOS) Reports Q2 Loss, Lags Revenue Estimates Zacks · 14 Aug 2026
- Aveanna Healthcare (AVAH) Beats Q2 Earnings and Revenue Estimates Zacks · 13 Aug 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-11 | Van Kirk Richard Lee Jr | CEO | S - Sale | 765 | $45,412 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $56.51 | +8.9% | · | $1,089 | +8.9% |
| 2 months | $51.48 | +19.5% | · | $1,195 | +19.5% |
| 3 months | $46.82 | +31.4% | · | $1,314 | +31.4% |
| 6 months | $43.57 | +41.2% | · | $1,412 | +41.2% |
| 1 year | $42.25 | +45.6% | · | $1,456 | +45.6% |
| 2 years | $19.58 | +214.2% | · | $3,142 | +214.2% |
| 3 years | $19.00 | +223.7% | · | $3,237 | +223.7% |
| 5 years | $32.24 | +90.8% | · | $1,908 | +90.8% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever PDEX does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.